Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 5, 2007

Adventrx Grants Manufacturing Contract for Novel Docetaxel Emulsion Product

  • Adventrx Pharmaceuticals entered into an agreement with Hyaluron Contract Manufacturing related to ANX-514 (docetaxel emulsion). It is a novel nano-emulsion formulation of the chemotherapy drug docetaxel. The candidate is designed to eliminate the need for multiday immunosuppressant premedication.

    Hyaluron will manufacture the product for preclinical and clinical studies. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions, according to Adventrx.

    "We anticipate seeking guidance from the Food and Drug Administration with regard to a 505(b)(2) regulatory path for ANX-514 and pending appropriate clearances, initiating a marketing-enabling clinical trial of ANX-514 later this year," says Evan M. Levine, CEO of Adventrx.

    Adventrx is conducting preclinical pharmacokinetic testing of ANX-514 to compare this product candidate with the approved version of the docetaxel, marketed under the brand name Taxotere.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »